Cite
BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer
MLA
Fouzia Azzouz, et al. “BIONIKK: A Phase 2 Biomarker Driven Trial with Nivolumab and Ipilimumab or VEGFR Tyrosine Kinase Inhibitor (TKI) in Naïve Metastatic Kidney Cancer.” Bulletin Du Cancer, vol. 107, June 2020, pp. eS22-eS27. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a22ee843de9dc8fb7014739dd70ddd8b&authtype=sso&custid=ns315887.
APA
Fouzia Azzouz, Audrey Simonaggio, Marco Moreira, Cheng-Ming Sun, Nicolas Epaillard, Elena Braychenko, Yann-Alexandre Vano, Stéphane Oudard, Reza Elaidi, & Constance Thibault. (2020). BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer. Bulletin Du Cancer, 107, eS22-eS27.
Chicago
Fouzia Azzouz, Audrey Simonaggio, Marco Moreira, Cheng-Ming Sun, Nicolas Epaillard, Elena Braychenko, Yann-Alexandre Vano, Stéphane Oudard, Reza Elaidi, and Constance Thibault. 2020. “BIONIKK: A Phase 2 Biomarker Driven Trial with Nivolumab and Ipilimumab or VEGFR Tyrosine Kinase Inhibitor (TKI) in Naïve Metastatic Kidney Cancer.” Bulletin Du Cancer 107 (June): eS22-eS27. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a22ee843de9dc8fb7014739dd70ddd8b&authtype=sso&custid=ns315887.